CDX
PANC-1
Tumor indication
Pancreatic
Tumor subtype
Pancreatic Ductal Adenocarcinoma
Description
PANC-1 (Pancreatic Cancer CDX Model)
The PANC-1 pancreatic cancer cell line was derived from a ductal adenocarcinoma of the pancreas. It carries a KRAS mutation, reflecting one of the most common drivers in pancreatic ductal adenocarcinoma (PDAC). PANC-1 exhibits aggressive biology and reproducible xenograft growth. Its stability makes it a widely used PDAC research model.
Key Features:
- Derived from pancreatic ductal adenocarcinoma.
- KRAS-mutant pancreatic model.
- Aggressive growth phenotype.
- Tumorigenic in xenografts.
Applications:
PANC-1 supports therapeutic development in pancreatic cancer. Researchers use it to evaluate chemotherapies, targeted therapies, and drug delivery approaches. It is also applied in biomarker and resistance studies. Its reproducibility ensures value across translational PDAC research.
Details
- Tumor indication
- Pancreatic
- Tumor subtype
- Pancreatic Ductal Adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.